IA sanitation worker, Ram Verma, merging with the New Delhi’s Holy Family Hospital, took a deep sigh of relief. As one of India’s first to receive the coronovirus vaccine on Saturday – marking the start of the world’s largest vaccination programs – he felt a bit nervous.
“I must admit I was nervous,” said Verma, who received his kovaxin jab at a center set up in the hospital car park. “There were many of us. I felt that I might faint or have side effects. After all, it is completely new. but I’m fine. there is nothing to worry about.”
Anila Singh, a nurse at the capital’s Ram Manohar Lohia Hospital, said she almost cried with relief when she heard that she was the first woman to receive the vaccine. “I thought of all the people I saw dying, all the families who had loved someone and had my own daily fears about catching the virus, it all came back,” she said. “Finally we are going to turn the page.”
In India, 3,006 vaccination centers started the mammoth task of vaccinating 300 million people by August, with health workers, police and members of the military taking first priority. India ranks second in the world for Kovid-19 cases, recording more than 10.5 million cases and more than 151,000 deaths.
Two vaccines have been granted emergency approval for India’s vaccination program: the Oxford / AstraZeneca vaccine, known in India as Covishield, and Covaxin, a home product produced by the Indian pharmaceutical company Bharat Biotech of the Indian Council of Medical Research Developed in conjunction, a government body.
It was a slow start on Saturday, but there was pressure to increase speed. Within a week, Mumbai plans to vaccinate 50,000 people per day, while in Delhi the figure is even more ambitious. Dr. who works in Delhi vaccinated. Sunila Garg said, “Once the city has 1,000 vaccination centers, we will do 100,000 vaccinations every day.”
Prime Minister Narendra Modi announced the launch of the vaccine program as a moment of pride for India, declaring that “it shows our potential to the world”. Nevertheless, a shadow hung the proceedings, as doctors, health rights advocates and scientists have questioned the adequacy and safety of kovaxine and accused the government of approving partisan protocols.
The vaccine has not completed Phase 3 human trials and there is no conclusive final data on its efficacy, placing India between Russia and China, who have decided to roll out a vaccine still in its testing phase. The government has said that kovaxine is “100% safe” and that 5.5 million doses of it were shipped across the country on Saturday, although they would be given in “trial mode”.
On Saturday, the Association of Resident Doctors of Ram Manohar Lohia Hospital wrote a letter to the superintendent of the hospital expressing concern about Kovaxin and requested that he be given permission to Kovishield instead.
Senior Resident Doctor and Association Vice President Dr. Nirmalya Mahapatra said: “There is a lot of apprehension because we do not have the same data for kovaxin. We are healthcare workers and we are concerned that kovaxin may not save us from another wave of infection as it is still under trial. So we are just requesting which vaccine we are given. “
Mohapatra said that with no alternative, it could lead to a widespread refusal among doctors to take the vaccine. At the Ram Manohar Lohia Hospital on Saturday, 31 out of 100 health workers were registered to be given the vaccine, partly due to technical bottlenecks but also responsible for concerns among staff that the hospital was only offering kovaxin is.
Bharat Biotech has also been accused of moral violations for testing Kovaxin on people in the slums of Bhopal in Madhya Pradesh, without knowing it was a test. Seven people have claimed that they were told they were receiving a vaccine that would protect them from the virus, and were paid Rs 750, without any awareness that it was a vaccine or that they had received a placebo could.
In a letter to the government, several health rights organizations, including the All India Drug Action Network, Forum for Medical Ethics Society and People’s Health Movement India, sought to stop the Kovaxin trial in Bhopal. He said, “Evidence shows an interest that violates the principle of voluntary participation or without coercion”. “Many participants were misled to enroll in the trial, falling prey to their weaknesses.”
Bharat Biotech denied any ethical violations and stated that the test fully complied with “good clinical practice guidelines and all regulatory provisions applicable to the conduct of clinical trials in India”.
The questions asked on Kovacsin also have not helped in the government’s desperate efforts to counter the hesitation and hesitation of misinformation and fake rumors about vaccines being aired on WhatsApp. On Wednesday, Delhi Chief Minister, Arvind Kejriwal appealed to the people to be vigilant against the misinformation of the vaccine.
At the Spinal Injuries Center in New Delhi, a surgeon Drs. Kali Dutt Das said that some fake rumors on WhatsApp about the vaccine had made the final moment of concern on Saturday. However, he remained upbeat. “We vaccinated 100 employees today and it was in a very positive mood because people felt that Kovid-19 finally has a solution,” Das said.